CLDX
Price
$23.78
Change
+$1.02 (+4.48%)
Updated
Jan 17 closing price
Capitalization
1.58B
44 days until earnings call
ELEV
Price
$0.71
Change
+$0.04 (+5.97%)
Updated
Jan 17 closing price
Capitalization
42.05M
46 days until earnings call
Ad is loading...

CLDX vs ELEV

Header iconCLDX vs ELEV Comparison
Open Charts CLDX vs ELEVBanner chart's image
Celldex Therapeutics
Price$23.78
Change+$1.02 (+4.48%)
Volume$854.67K
Capitalization1.58B
Elevation Oncology
Price$0.71
Change+$0.04 (+5.97%)
Volume$2.29M
Capitalization42.05M
CLDX vs ELEV Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELEV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. ELEV commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and ELEV is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CLDX: $23.78 vs. ELEV: $0.71)
Brand notoriety: CLDX and ELEV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 81% vs. ELEV: 99%
Market capitalization -- CLDX: $1.58B vs. ELEV: $42.05M
CLDX [@Biotechnology] is valued at $1.58B. ELEV’s [@Biotechnology] market capitalization is $42.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileELEV’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • ELEV’s FA Score: 1 green, 4 red.
According to our system of comparison, both CLDX and ELEV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 4 TA indicator(s) are bullish while ELEV’s TA Score has 6 bullish TA indicator(s).

  • CLDX’s TA Score: 4 bullish, 3 bearish.
  • ELEV’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ELEV is a better buy in the short-term than CLDX.

Price Growth

CLDX (@Biotechnology) experienced а -2.34% price change this week, while ELEV (@Biotechnology) price change was +9.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CLDX is expected to report earnings on May 13, 2025.

ELEV is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.58B) has a higher market cap than ELEV($42.1M). ELEV YTD gains are higher at: 26.431 vs. CLDX (-5.896). ELEV has higher annual earnings (EBITDA): -43.11M vs. CLDX (-171.06M). CLDX has more cash in the bank: 756M vs. ELEV (103M). CLDX has less debt than ELEV: CLDX (3.09M) vs ELEV (31M). CLDX has higher revenues than ELEV: CLDX (9.98M) vs ELEV (0).
CLDXELEVCLDX / ELEV
Capitalization1.58B42.1M3,748%
EBITDA-171.06M-43.11M397%
Gain YTD-5.89626.431-22%
P/E RatioN/AN/A-
Revenue9.98M0-
Total Cash756M103M734%
Total Debt3.09M31M10%
FUNDAMENTALS RATINGS
CLDX: Fundamental Ratings
CLDX
OUTLOOK RATING
1..100
54
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
48
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CLDXELEV
RSI
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
75%
Bearish Trend 11 days ago
90%
Momentum
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 11 days ago
82%
MACD
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 11 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 11 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 13 days ago
87%
Declines
ODDS (%)
Bearish Trend 20 days ago
79%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 11 days ago
86%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELEV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TPST0.930.03
+3.41%
Tempest Therapeutics
GILT6.670.09
+1.37%
Gilat Satellite Networks Ltd
OMCL42.570.43
+1.02%
Omnicell
CM62.66-0.06
-0.10%
Canadian Imperial Bank of Commerce
MDU18.41-0.04
-0.22%
MDU Resources Group

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KRYS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+4.48%
KRYS - CLDX
56%
Loosely correlated
+2.47%
ALT - CLDX
45%
Loosely correlated
+2.24%
AXON - CLDX
43%
Loosely correlated
+1.37%
NTLA - CLDX
42%
Loosely correlated
+0.85%
BEAM - CLDX
42%
Loosely correlated
+0.17%
More

ELEV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELEV has been loosely correlated with TBPH. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ELEV jumps, then TBPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELEV
1D Price
Change %
ELEV100%
+6.24%
TBPH - ELEV
46%
Loosely correlated
+1.66%
NKTX - ELEV
38%
Loosely correlated
-0.80%
BOLT - ELEV
31%
Poorly correlated
-1.61%
CLDX - ELEV
27%
Poorly correlated
+4.48%
RCUS - ELEV
27%
Poorly correlated
-0.64%
More